Founded in 1928, UCB transformed itself over time to become a global bio-pharmaceutical company, inspired by patients; driven by science. The 7,600 of UCB’s colleagues and its partners are focused on creating value for people living with severe diseases in immunology and neurology now and into the future. With more than 90 years’ experience, UCB acknowledges its responsibility to drive positive change in society and contribute to the United Nation’s Sustainable Development Goals (SDGs). UCB considers sustainability as a true business approach and believes that through its experience in healthcare and partnerships/networks the most impact can be made by focusing on SDGs: SDG#3 which is about ensuring healthy lives and promoting well-being for all at all ages and SDG#17 which leads all stakeholders to strengthen the means of implementation and revitalize the global partnership for sustainable development.


The Shift aide ses membres à utiliser le cadre international des Objectifs de développement durable de l'ONU pour définir leurs ambitions sociales.

3. Good health

UCB focuses its efforts on four areas that are critical to long-term success and contribution to society alongside financial performance: continuously innovate to bring differentiated medicines to patients; improve patient access to UCB’s solutions; promote employees’ health, safety & well-being and minimize environmental footprint.

17. Partnerships for the goals

To fulfil UCB’s ambition, UCB must create the right conditions for its employees, the communities in which they operate, and their shareholders. UCB cannot do this alone and should embrace partnership with other key healthcare system stakeholders (regulators, payors, HCPs, patient associations, etc.).